Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis - Scorecard - MDSpire
Advertisement
Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis
Clinical Scorecard: Pharmacokinetic and Pharmacodynamic Profiles of Pretomanid, Delamanid, and Bedaquiline in a BALB/c Mouse Model of Central Nervous System Tuberculosis
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients with CNS-TB, particularly those with drug-resistant forms.
Care Setting
Key Highlights
highlight_5
Guideline-Based Recommendations
Diagnosis
Management
First-line drugs for drug-susceptible CNS-TB include isoniazid, rifampicin, ethambutol, and pyrazinamide; MDR-TB requires a combination of drugs from groups A, B, and C.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with CNS-TB, particularly those with multidrug-resistant strains.
New drugs may be effective but require further investigation for CNS-TB treatment.
Clinical Best Practices
Prompt initiation of anti-tuberculosis therapy is critical in CNS-TB.
Consideration of drug penetration into CNS is essential when selecting treatment regimens.
Monitor for potential drug interactions when prescribing new anti-TB drugs.
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
